Iterion Therapeutics

Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The companys lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma

Iterion therapeutics operates in the Biotechnology research industry.

Iterion therapeutics's revenue is 11m - 100m

Iterion therapeutics has 11 - 50 employees.